Generic Evzio Availability
Last updated on Apr 10, 2025.
Evzio is a brand name of naloxone, approved by the FDA in the following formulation(s):
EVZIO (naloxone hydrochloride - solution;intramuscular, subcutaneous)
-
Manufacturer: KALEO INC
Approval date: April 3, 2014
Strength(s): 0.4MG/0.4ML (0.4MG/0.4ML) (discontinued) [RLD] -
Manufacturer: KALEO INC
Approval date: October 19, 2016
Strength(s): 2MG/0.4ML (2MG/0.4ML) (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evzio. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Patent 10,143,792
Issued: December 4, 2018
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Blondino Frank E.
Assignee(s): kaleo, Inc.Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
Patent expiration dates:
- May 24, 2031✓
- May 24, 2031
-
Ultrafiltration membrane and a preparation method thereof
Patent 10,143,972
Issued: December 4, 2018
Inventor(s): Li Jiansheng & Pan Shunlong & Fang Xiaofeng & Wang Lianjun & Sun Xiuyun & Shen Jinyou & Han Weiqing & Liu Xiaodong
Assignee(s): NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGYThe present invention provides an ultrafiltration membrane comprising a sulfone polymer membrane matrix with pores and an organic polymer sealing layer, wherein the pores are filled with nanoadsorbents. The present invention further provides a method for preparing the ultrafiltration membrane, which includes the following steps: (1) synthesizing nanoadsorbents; (2) preparing the sulfone polymer membrane matrix by immersion-precipitation phase inversion; and (3) immobilizing nanoadsorbents in the pores of the sulfone polymer membrane matrix by reverse filling, then sealing the pores with organic polymers to form a multifunctional ultrafiltration membrane. In the present invention, colloidal gold, polyethylene glycol molecules and Pb(II) ions (and so forth) are utilized as models of viruses, macromolecular organic pollutants, and small molecular pollutants, respectively. It is shown that the multifunctional ultrafiltration membrane allows for removal of multiple pollutants from water and can simultaneously remove multiple pollutants under low pressure.
Patent expiration dates:
- May 24, 2031✓
- May 24, 2031
-
Devices and methods for delivering opioid antagonists including formulations for naloxone
Patent 10,220,158
Issued: March 5, 2019
Inventor(s): Blondino Frank E. & Edwards Eric S. & Edwards Evan T. & Kelley Glen L. & Meyers Paul F.
Assignee(s): kaleo, Inc.An apparatus includes a container, a needle, and an actuation assembly. The container contains a dose of a naloxone composition having a delivered volume of at least about 0.34 mL. The actuation assembly includes an energy storage member that produces a force on a movable member to move the needle and to deliver the dose of the naloxone composition. The 90% confidence interval of at least one of the relative mean maximum naloxone plasma concentration after dose delivery into the body (C), time to reach the maximum naloxone plasma concentration (T), area under the plasma concentration-time curve from pre-dose (time 0) extrapolated to infinity (AUC), or area under the plasma concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (T) (AUC) of the delivered dose to a delivered dose of a corresponding naloxone composition delivered via a manually-actuated syringe is within 80% to 125%.
Patent expiration dates:
- March 20, 2035✓✓
- March 20, 2035
-
Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Patent 10,322,239
Issued: June 18, 2019
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Meyers Paul F. & Blondino Frank E.
Assignee(s): kaleo, Inc.Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH-adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
Patent expiration dates:
- February 28, 2031✓
- February 28, 2031
-
Devices, systems and methods for medicament delivery
Patent 10,335,549
Issued: July 2, 2019
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Meyers Paul F.
Assignee(s): kaleo, Inc.A method includes moving an actuation lock of a medical injector from a first position to a second position. The actuation lock has an extended portion disposed between a shoulder of a housing and the base when the actuation lock is in the first position. The extended portion is spaced apart from the base when the actuation lock is in the second position. A distal end portion of a base, which is movably coupled to an end portion of the housing, is placed into contact with a body. The base is actuated after the placing to release an energy from an energy storage member within the housing to produce a force to move a needle from a first needle position to a second needle position. At least a portion of the needle extends through the base when the needle is in the second needle position.
Patent expiration dates:
- April 30, 2025✓
- April 30, 2025
-
Devices, systems and methods for medicament delivery
Patent 10,960,155
Issued: March 30, 2021
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Meyers Paul F. & Weinzierl David A.
Assignee(s): kaleo, Inc.An apparatus includes a label configured to be coupled to a medicament delivery device. The label includes a first surface and a second surface. The first surface is configured to be coupled to an outer surface of the medicament delivery device. The second surface includes a textual indicia. The label further includes an electronic circuit system configured to output an electronic signal.
Patent expiration dates:
- June 25, 2026✓
- June 25, 2026
-
Devices, systems and methods for medicament delivery
Patent 11,590,286
Issued: February 28, 2023
Inventor(s): Edwards; Eric S. et al.
Assignee(s): kaleo, Inc. (Richmond, VA)A method includes moving an actuation lock of a medical injector from a first position to a second position. The actuation lock has an extended portion disposed between a shoulder of a housing and the base when the actuation lock is in the first position. The extended portion is spaced apart from the base when the actuation lock is in the second position. A distal end portion of a base, which is movably coupled to an end portion of the housing, is placed into contact with a body. The base is actuated after the placing to release an energy from an energy storage member within the housing to produce a force to move a needle from a first needle position to a second needle position. At least a portion of the needle extends through the base when the needle is in the second needle position.
Patent expiration dates:
- December 12, 2026✓
- December 12, 2026
-
Devices, systems and methods for medicament delivery
Patent 7,731,686
Issued: June 8, 2010
Inventor(s): Edwards; Eric Shawn et al.
Assignee(s): Intelliject, Inc. (Richmond, VA)An apparatus includes a label configured to be coupled to a medicament delivery device. The label includes a first surface and a second surface. The first surface is configured to be coupled to an outer surface of the medicament delivery device. The second surface includes a textual indicia. The label further includes an electronic circuit system configured to output an electronic signal.
Patent expiration dates:
- June 10, 2026✓
- June 1, 2026✓
- June 10, 2026
-
Devices, systems and methods for medicament delivery
Patent 7,731,690
Issued: June 8, 2010
Inventor(s): Edwards; Eric Shawn et al.
Assignee(s): Intelliject, Inc. (Richmond, VA)An apparatus includes a housing, a medicament container, an actuator, and a biasing member. The actuator is configured to move the medicament container within the housing when the actuator is moved from a first configuration to a second configuration. The actuator includes a gas container and a puncturer. When the actuator is in the first configuration, a portion of the puncturer is disposed apart from the gas container. When the actuator is in the second configuration, the portion of the puncturer is disposed within the gas container. The gas container has a longitudinal axis offset from a longitudinal axis of the medicament container. The biasing member is configured to bias the actuator toward the second configuration.
Patent expiration dates:
- January 15, 2025✓
- January 15, 2025
-
Devices, systems, and methods for medicament delivery
Patent 7,749,194
Issued: July 6, 2010
Inventor(s): Edwards; Evan T. et al.
Assignee(s): Intelliject, Inc. (Richmond, VA)Certain exemplary embodiments comprise can comprise an auto-injector, which can comprise: a vial configured to store and/or contain an injectable medicament, the vial defining a vial longitudinal axis, and a housing comprising the vial. In various embodiments, the injectable medicament can be a medicine, medication, drug, pharmaceutical, prescriptive, agent, antidote, anti-venom, hormone, stimulant, vasodilator, anesthetic, and/or nutritional supplement that is substantially ready for injection.
Patent expiration dates:
- October 30, 2028✓
- October 30, 2028
-
Devices, systems and methods for medicament delivery
Patent 7,947,017
Issued: May 24, 2011
Inventor(s): Edwards; Evan Thomas et al.
Assignee(s): Intelliject, Inc. (Richmond, VA)An apparatus includes a movable member and a valve coupled to the movable member. The movable member is configured to be disposed within a housing of a medical device and has a first end portion and second end portion. A portion of the first end portion is configured to define a portion of a boundary of a gas chamber. The first end portion defines an opening configured to be in fluid communication between the gas chamber and an area outside the gas chamber. The second end portion is configured to be coupled to a needle configured to deliver a medicament into a body. The valve is configured to selectively allow fluid communication between the gas chamber and the area outside the gas chamber through the opening defined by the first end portion of the movable member.
Patent expiration dates:
- March 12, 2028✓
- March 12, 2028
-
Devices, systems and methods for medicament delivery
Patent 8,016,788
Issued: September 13, 2011
Inventor(s): Edwards; Evan Thomas et al.
Assignee(s): Intelliject, Inc. (Richmond, VA)An apparatus includes a housing, a medicament container and an actuator. The actuator includes a release member and an energy storage member having a first position and a second position. In the first position, the energy storage member has a first potential energy. In the second position the energy storage member has a second potential energy. The energy storage member is configured to convert a portion of the first potential energy into kinetic energy when moved from the first position to the second position to move the medicament container within the housing. The energy storage member has a longitudinal axis offset from a longitudinal axis of the medicament container. The release member is configured to selectively deploy the energy storage member from its first position to its second position.
Patent expiration dates:
- March 21, 2025✓
- March 21, 2025
-
Medicament delivery device configured to produce an audible output
Patent 8,021,344
Issued: September 20, 2011
Inventor(s): Edwards; Eric S. et al.
Assignee(s): Intelliject, Inc. (Richmond, VA)Medicament delivery devices are described herein. In some embodiments, an apparatus includes a medicament delivery device and an electronic circuit system. The medicament delivery device includes a housing, a medicament container, and a medicament delivery member. The electronic circuit system is coupled to the housing and includes an audible output device and a cover. The housing of the medicament delivery device and the cover of the electronic circuit system collectively define an acoustic enclosure. The audible output device is configured to be disposed within the acoustic enclosure.
Patent expiration dates:
- November 2, 2029✓
- November 2, 2029
-
Devices, systems and methods for medicament delivery
Patent 8,206,360
Issued: June 26, 2012
Inventor(s): Edwards Eric Shawn & Edwards Evan Thomas & Licata Mark J. & Meyers Paul F. & Weinzierl David A.
Assignee(s): Intelliject, Inc.An apparatus includes a label configured to be coupled to a medicament delivery device. The label includes a first surface and a second surface. The first surface is configured to be coupled to an outer surface of the medicament delivery device. The second surface includes a textual indicia. The label further includes an electronic circuit system configured to output an electronic signal.
Patent expiration dates:
- February 27, 2027✓
- February 27, 2027
-
Medical injector with compliance tracking and monitoring
Patent 8,226,610
Issued: July 24, 2012
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Meyers Paul F. & Weinzierl David A. & Williamson & IV T. Spencer
Assignee(s): Intelliject, Inc.A system includes a medicament delivery device and a container configured to receive at least a portion of the medicament delivery device. The medicament delivery device includes an actuator and a first electronic circuit system. The actuator is configured to initiate delivery of a medicament into a body when the actuator is moved from a first position to a second position. The first electronic circuit system is configured to output a first electronic signal when the actuator is moved from the first position to the second position. The container includes a second electronic circuit system configured to receive the first electronic signal. The second electronic circuit system is configured to output a second electronic signal associated with the first electronic signal.
Patent expiration dates:
- April 10, 2029✓
- April 10, 2029
-
Medicament delivery device having an electronic circuit system
Patent 8,231,573
Issued: July 31, 2012
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Meyers Paul F. & Weinzierl David A.
Assignee(s): Intelliject, Inc.Medicament delivery devices are described herein. In some embodiments, an apparatus includes a medical injector and an electronic circuit system. The medical injector includes a housing, a medicament container, and a medicament delivery member. The housing defines a first region and a second region. The first region includes the medicament container and is physically isolated from the second region. The electronic circuit system is configured to be disposed within the second region defined by the housing. The electronic circuit system is configured to output an electronic output associated with a use of the medical injector.
Patent expiration dates:
- November 25, 2028✓
- November 25, 2028
-
Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Patent 8,627,816
Issued: January 14, 2014
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Blondino Frank E.
Assignee(s): Intelliject, Inc.Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
Patent expiration dates:
- February 4, 2032✓
- February 4, 2032
-
Devices, systems and methods for medicament delivery
Patent 8,926,594
Issued: January 6, 2015
Inventor(s): Edwards Eric Shawn & Edwards Evan Thomas & Licata Mark J. & Meyers Paul F. & Weinzierl David A.
Assignee(s): kaleo, Inc.An apparatus includes a label configured to be coupled to a medicament delivery device. The label includes a first surface and a second surface. The first surface is configured to be coupled to an outer surface of the medicament delivery device. The second surface includes a textual indicia. The label further includes an electronic circuit system configured to output an electronic signal.
Patent expiration dates:
- March 31, 2026✓
- March 31, 2026
-
Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Patent 8,939,943
Issued: January 27, 2015
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Meyers Paul F. & Blondino Frank E.
Assignee(s): kaleo, Inc.Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH-adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
Patent expiration dates:
- February 28, 2031✓
- February 28, 2031
-
Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Patent 9,022,022
Issued: May 5, 2015
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Blondino Frank E.
Assignee(s): kaleo, Inc.Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
Patent expiration dates:
- February 28, 2031✓
- February 28, 2031
-
Medicament delivery device having an electronic circuit system
Patent 9,238,108
Issued: January 19, 2016
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Meyers Paul F. & Weinzierl David A.
Assignee(s): kaleo, Inc.Medicament delivery devices are described herein. In some embodiments, an apparatus includes a medical injector and an electronic circuit system. The medical injector includes a housing, a medicament container, and a medicament delivery member. The housing defines a first region and a second region. The first region includes the medicament container and is physically isolated from the second region. The electronic circuit system is configured to be disposed within the second region defined by the housing. The electronic circuit system is configured to output an electronic output associated with a use of the medical injector.
Patent expiration dates:
- February 20, 2027✓
- February 20, 2027
-
Devices, systems and methods for medicament delivery
Patent 9,278,182
Issued: March 8, 2016
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Meyers Paul F. & Weinzierl David A.
Assignee(s): kaleo, Inc.An apparatus includes a label configured to be coupled to a medicament delivery device. The label includes a first surface and a second surface. The first surface is configured to be coupled to an outer surface of the medicament delivery device. The second surface includes a textual indicia. The label further includes an electronic circuit system configured to output an electronic signal.
Patent expiration dates:
- February 1, 2026✓
- February 1, 2026
-
Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Patent 9,474,869
Issued: October 25, 2016
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Blondino Frank E.
Assignee(s): kaleo, Inc.Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
Patent expiration dates:
- February 28, 2031✓✓
- February 28, 2031
-
Devices and methods for delivering opioid antagonists including formulations for naloxone
Patent 9,517,307
Issued: December 13, 2016
Inventor(s): Blondino Frank E. & Edwards Eric S. & Edwards Evan T. & Kelley Glen L. & Meyers Paul F.
Assignee(s): kaleo, Inc.An apparatus includes a container, a needle, and an actuation assembly. The container contains a dose of a naloxone composition having a delivered volume of at least about 0.34 mL. The actuation assembly includes an energy storage member that produces a force on a movable member to move the needle and to deliver the dose of the naloxone composition. The 90% confidence interval of at least one of the relative mean maximum naloxone plasma concentration after dose delivery into the body (C), time to reach the maximum naloxone plasma concentration (T), area under the plasma concentration-time curve from pre-dose (time 0) extrapolated to infinity (AUC), or area under the plasma concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (T) (AUC) of the delivered dose to a delivered dose of a corresponding naloxone composition delivered via a manually-actuated syringe is within 80% to 125%.
Patent expiration dates:
- July 18, 2034✓✓
- July 18, 2034
-
Devices, systems, and methods for medicament delivery
Patent 9,724,471
Issued: August 8, 2017
Inventor(s): Edwards Evan T. & Edwards Eric S. & Licata Mark J.
Assignee(s): kaleo, Inc.Certain exemplary embodiments comprise can comprise an auto-injector, which can comprise: a vial configured to store and/or contain an injectable medicament, the vial defining a vial longitudinal axis, and a housing comprising the vial. In various embodiments, the injectable medicament can be a medicine, medication, drug, pharmaceutical, prescriptive, agent, antidote, anti-venom, hormone, stimulant, vasodilator, anesthetic, and/or nutritional supplement that is substantially ready for injection.
Patent expiration dates:
- May 23, 2027✓✓
- May 23, 2027
More about Evzio (naloxone)
- Evzio consumer information
- Check interactions
- Compare alternatives
- Reviews (1)
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antidotes
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.